Diffuse Large Cell Lymphoma

Diffuse Large Cell Lymphoma

In this, the second of three videos in which Sunita Nasta, MD, FACP reviews findings from ASH on the aggressive lymphomas, Dr. Nasta considers diffuse large B cell lymphomas (DLBCL). Among other advances, her presentation includes an overview of current investigational targeted therapies and a consideration of RCHOP therapies, as well as the introduction of two agents, a novel, oral dual inhibitor of histone deacetylas and P13K and venetoclax monotherapy, for patients with relapsed/refractory DLBCL.

For more than 20 years, BroadcastMed has been innovating digital strategies for healthcare organizations. The company was first in the world to broadcast live surgeries on the internet using its ORLive solution which provides an intimate look inside the operating room.